Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) EBITDA Margin (2019 - 2025)

Cyclerion Therapeutics has reported EBITDA Margin over the past 6 years, most recently at 111.54% for Q3 2025.

  • Quarterly results put EBITDA Margin at 111.54% for Q3 2025, up 26114.0% from a year ago — trailing twelve months through Sep 2025 was 126.2% (up 265112.0% YoY), and the annual figure for FY2024 was 181.4%, changed.
  • EBITDA Margin for Q3 2025 was 111.54% at Cyclerion Therapeutics, up from 1797.85% in the prior quarter.
  • Over the last five years, EBITDA Margin for CYCN hit a ceiling of 27.8% in Q4 2024 and a floor of 21611.29% in Q1 2021.
  • Median EBITDA Margin over the past 4 years was 1798.77% (2025), compared with a mean of 3486.65%.
  • Biggest five-year swings in EBITDA Margin: tumbled -1961662bps in 2021 and later skyrocketed 1978597bps in 2022.
  • Cyclerion Therapeutics' EBITDA Margin stood at 2690.06% in 2021, then plummeted by -63bps to 4389.87% in 2022, then skyrocketed by 101bps to 27.8% in 2024, then crashed by -501bps to 111.54% in 2025.
  • The last three reported values for EBITDA Margin were 111.54% (Q3 2025), 1797.85% (Q2 2025), and 1798.77% (Q1 2025) per Business Quant data.